



Note

Chemical constituents from the roots of *Cynanchum paniculatum* and their cytotoxic activity



Chung Sub Kim^a, Ju Yeoun Oh^a, Sang Un Choi^b, Kang Ro Lee^{a,*}

^a Natural Products Laboratory, School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea

^b Korea Research Institute of Chemical Technology, Daejeon 305-343, Republic of Korea

ARTICLE INFO

Article history:

Received 13 July 2013

Received in revised form 22 August 2013

Accepted 23 August 2013

Available online 4 September 2013

Keywords:

Cynanchum paniculatum

Asclepiadaceae

Steroidal glycosides

Cytotoxicity

ABSTRACT

Two new steroidal saponins, cynanside A (**1**) and B (**2**) were isolated together with three known compounds (**3–5**) from the roots of *Cynanchum paniculatum* (Bunge) Kitag. The structures of **1** and **2** were elucidated on the basis of spectroscopic analyses, including extensive 2D NMR and acid hydrolysis. We evaluated the cytotoxicity of isolates (**1–5**) against A549, SK-OV-3, SK-MEL-2, and HCT-15 cell lines in vitro using the SRB bioassay. Compounds **1** and **2** showed selective cytotoxicity against SK-MEL-2 cells with IC₅₀ values of 26.55 and 17.36 μM, respectively.

© 2013 Elsevier Ltd. All rights reserved.

Steroidal saponins have been isolated from various plant sources. They possess a wide range of pharmacological activities including cytotoxicity.^{1–5} Among them, C21 steroidal saponins from the genus *Cynanchum* exhibit antitumor and cytotoxic activities.^{6–9} As a part of our ongoing search for cytotoxic constituents from Korean medicinal sources, MeOH extract of the roots of *Cynanchum paniculatum* (Bunge) Kitag (Asclepiadaceae) was selected for phytochemical investigation because the *n*-hexane and CHCl₃-soluble fractions showed cytotoxic activity using a SRB bioassay in our screening procedures. Our previous phytochemical investigation on MeOH extract of this source resulted in the isolation of seven C21 steroidal saponins.¹⁰ In our continuing study on this source, we further isolated two new C21 steroidal saponins (**1** and **2**) from the active CHCl₃-soluble fraction and three known compounds (**3–5**) from the *n*-hexane-soluble fraction. Their structures were elucidated by 1D and 2D NMR, HR-FAB-MS, acid hydrolysis, and GC/MS. We also evaluated the cytotoxicities of isolates **1–5** (see Fig. 1).

Cynanside A (**1**) was obtained as an amorphous gum. The molecular formula was determined as C₄₂H₆₄O₁₅ from the molecular ion peak [M+Na]⁺ at *m/z* 831.4144 (calcd for C₄₂H₆₄NaO₁₅, 831.4143) in positive ion HR-FAB-MS. The ¹³C NMR data (Table 1) in combination with analysis of the DEPT and HMQC spectra revealed 42 carbon signals due to eight methyls, nine methylenes, 20 methines, and five quaternary carbons, of which 22 were assigned to the aglycone part including one carbonyl carbon (δ_C

179.3) and four olefinic carbons (δ_C 142.2, 140.0, 131.1, and 120.1). The remaining 20 carbons were ascribed to three sugars and two methoxy groups. The NMR spectral data including ¹H NMR, DEPT, ¹H–¹H COSY, HMQC, and HMBC spectra showed the presence of two oxygenated methines [δ_H 5.73 (1H, ddd, *J* = 8.0, 7.5, 5.0 Hz, H-16), 3.75 (1H, m, H-3)], one acetal methine [δ_H 5.59 (1H, s, H-18)], two olefinic methines [δ_H 5.48 (1H, dd, *J* = 11.0, 5.0 Hz, H-12), 5.37 (1H, m, H-6)], one oxygenated methylene [δ_H 4.42 (1H, dd, *J* = 10.0, 7.5 Hz, H-15a), 4.12 (1H, dd, *J* = 10.0, 5.0 Hz, H-15b)], one methoxy group [δ_H 3.49 (3H, s, H-18-OCH₃)], and two methyl groups [δ_H 1.71 (3H, s, H-21), 0.95 (3H, s, H-19)] of the aglycone part, and three anomeric protons [δ_H 5.55 (1H, dd, *J* = 10.0, 2.0 Hz, H-1''), 5.25 (1H, d, *J* = 3.0 Hz, H-1'''), 4.81 (1H, dd, *J* = 10.0, 2.0 Hz, H-1')], two methoxy groups [δ_H 3.57 (3H, s, H-3'-OCH₃), 3.33 (3H, s, H-3'''-OCH₃)], and three methyl groups [δ_H 1.51 (3H, d, *J* = 6.5 Hz, H-6'''), 1.45 (3H, d, *J* = 6.0 Hz, H-6''), 1.45 (3H, d, *J* = 6.0 Hz, H-6')] of the sugar moiety. These spectroscopic data of the aglycone part were similar to those of staurogenin 3-*O*-α-oleandropyranosyl-(1→4)-β-digitoxopyranosyl-(1→4)-β-oleandropyranoside¹⁰ except for the replacement of carbonyl carbon (δ_C 167.5) with acetal carbon (δ_C 104.2), and the presence of an additional methoxy carbon (δ_C 55.0). This was confirmed by HMBC correlations of H-18-OCH₃/C-18, H-18/C-12, and C-20 (Fig. 2). The sugar moiety was assumed to be α-L-oleandropyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-oleandropyranosyl group by comparing the ¹H and ¹³C NMR spectra with those of amplexicoside B¹¹ and confirmed through HMBC correlations of H-1'/C-3, H-1''/C-4', and H-1'''/C-4'' (Fig. 2). The anomeric configuration of sugars was determined by *J* values at C-1' (dd, *J* = 10.0,

* Corresponding author. Tel.: +82 31 290 7710; fax: +82 31 290 7730.

E-mail address: krlee@skku.edu (K.R. Lee).




Figure 1. Chemical structures of compounds 1 and 2.

2.0 Hz), C-1'' (dd, $J = 10.0, 2.0$ Hz), and C-1''' (d, $J = 3.0$ Hz) as β -, β -, and α -form, respectively. Acid hydrolysis of 1 afforded steroidal sapogenin, cynangenin A (1a), which was identified as 3 β -hydroxy-18 α -methoxy-15,20 α :18,20 β -diepoxy-13,14:14,15-disecopregna-5,12-dien-14-oic acid 16-oxylactone by ¹H NMR, HR-FAB-MS (m/z 391.2123 [M+H]⁺ (calcd for C₂₂H₃₁O₆, 391.2121)), and optical rotation $\{[\alpha]_D^{25} -17.5$ (c 0.05, MeOH)}, and three sugars (β -oleandrose, β -oleandrose, and β -digitoxose). Identification of β -oleandrose and β -digitoxose was performed by GC/MS analysis,¹² co-TLC with standard samples, and comparison of R_f values with the literature.¹³ β -Oleandrose could be identified by comparison of its spectroscopic data with those reported in the literatures.^{11,14} The relative configuration of 1 was assumed to be the same as that

of stauntonigen 3-O- α -oleandropyranosyl-(1 \rightarrow 4)- β -digitoxopyranosyl-(1 \rightarrow 4)- β -oleandropyranoside based on J values [δ_H 5.73 (1H, ddd, $J = 8.0, 7.5, 5.0$ Hz, H-16), 4.42 (1H, dd, $J = 10.0, 7.5$ Hz, H-15a), 4.12 (1H, dd, $J = 10.0, 5.0$ Hz, H-15b)]¹⁰ and confirmed by NOESY correlations of H-8/H-19, H-12/H-9 and H-17, H-16/H-17 and H-21, and H-18-OCH₃/H-21 (Fig. 2). Thus, the structure of 1 was determined to be 3 β -hydroxy-18 α -methoxy-15,20 α :18,20 β -diepoxy-13,14:14,15-disecopregna-5,12-dien-14-oic acid 16-oxylactone 3-O- α - β -oleandropyranosyl-(1 \rightarrow 4)- β - β -digitoxopyranosyl-(1 \rightarrow 4)- β - β -oleandropyranoside, which was designated cynanside A.

Cynanside B (2), an amorphous gum, exhibited a molecular formula of C₄₂H₆₄O₁₅ by the molecular ion peak [M+Na]⁺ at m/z 831.4144 (calcd for C₄₂H₆₄NaO₁₅, 831.4143) by HR-FAB-MS. The ¹H and ¹³C NMR data (Table 2) of the aglycone part of 2 were almost identical to those of cynanside I¹⁴ and we confirmed the aglycone structure of 2 to be glaucogenin A¹⁴ through DEPT and 2D NMR spectra (¹H-¹H COSY, HMQC, HMBC, and NOESY). The sugar moiety of 2 was assumed to be α - β -cymaropyranosyl-(1 \rightarrow 4)- β - β -cymaropyranosyl-(1 \rightarrow 4)- β - β -oleandropyranosyl group observing the similarity of ¹H and ¹³C NMR data to those of stauntonoside K¹² except for the presence of a methoxy signal (δ_H 3.55; δ_C 58.3) at C-3'' and upfield shift of C-3'' signal from δ_C 67.9 to 77.8. From the HMBC correlation of H-3'-OCH₃/C-3'' (Fig. 2), we confirmed the location of an additional methoxy group at C-3''. The anomeric configuration of sugars was deduced by J values at C-1' (dd, $J = 9.5, 2.0$ Hz), C-1'' (dd, $J = 9.5, 2.0$ Hz), and C-1''' (dd, $J = 4.5, 1.0$ Hz) as β -, β -, and α -form, respectively, and the sugar sequences were confirmed through the HMBC correlations of H-1'/C-3, H-1''/C-4', and H-1'''/C-4'' (Fig. 2). Acid hydrolysis of 2 gave aglycone, glaucogenin A (2a), which was identified through ¹H NMR and MS spectra with previously reported data,¹⁴ and β -oleandrose, β -cymarose, and β -cymarose. Identification of β -oleandrose was performed as that of 1 and β -cymarose and β -cymarose were to be identified by comparison of their spectroscopic data and R_f

Table 1 ¹H and ¹³C NMR spectroscopic data in C₅D₅N for compound 1^a

Position	Aglycone		Position	Sugar	
	δ_H	δ_C		δ_H	δ_C
1a	1.71 m	37.1 t	1'(β -Ole)	4.81 dd (10.0, 2.0)	98.0 d
1b	1.06 td (13.5, 4.0)		2'a	2.44 m	38.0 t
2a	2.06 br d (13.5)	30.1 t	2'b	1.80 m	
2b	1.66 m		3'	3.60 m	79.1 d
3	3.75 m	77.0 d	4'	3.57 m	83.2 d
4a	2.59 m	38.9 t	5'	3.56 m	71.7 d
4b	2.35 m		6'	1.45 d (6.0)	18.8 q
5		140.0 s	3'-OCH ₃	3.57 s	57.5 q
6	5.37 m	120.1 d	1''(β -Dig)	5.55 dd (10.0, 2.0)	98.6 d
7a	2.46 m	30.3 t	2''a	2.43 m	39.9 t
7b	2.25 m		2''b	2.00 br t (10.0)	
8	2.47 m	41.3 d	3''	4.61 br s	67.8 d
9	1.98 m	51.9 d	4''	3.54 m	82.3 d
10		37.6 s	5''	4.41 m	68.9 d
11a	2.42 m	29.9 t	6''	1.46 d (6.0)	18.6 q
11b	1.99 m		1'''(α -Ole)	5.25 d (3.0)	100.2 d
12	5.48 dd (11.0, 5.0)	131.1 d	2'''a	2.49 m	35.7 t
13		142.2 s	2'''b	1.73 m	
14		179.3 s	3'''	3.84 m	78.7 d
15a	4.42 dd (10.0, 7.5)	70.4 t	4'''	3.53 m	76.8 d
15b	4.12 dd (10.0, 5.0)		5'''	4.43 m	69.4 d
16	5.73 ddd (8.0, 7.5, 5.0)	78.0 d	6'''	1.51 d (6.5)	18.4 q
17	3.29 d (8.0)	56.0 d	3'''-OCH ₃	3.33 s	57.0 q
18	5.59 s	104.2 d			
19	0.95 s	19.5 q			
20		114.6 s			
21	1.71 s	24.2 q			
18-OCH ₃	3.49 s	55.0 q			

^a The assignments were based on DEPT, ¹H-¹H COSY, HMQC, and HMBC experiments. δ in ppm, J values in parentheses.




Figure 2. Key HMBC, ^1H - ^1H COSY and NOESY correlations of compounds **1** and **2**.

Table 2

^1H and ^{13}C NMR spectroscopic data in $\text{C}_5\text{D}_5\text{N}$ for compound **2**^a

Position	Aglycone		Position	Sugar	
	δ_{H}	δ_{C}		δ_{H}	δ_{C}
1a	2.49 m	44.7 t	1'(β -D-Ole)	4.79 dd (9.5, 2.0)	98.9 d
1b	1.27 t (12.0)		2'a	2.45 m	37.6 t
2	4.04 m	69.8 d	2'b	1.79 m	
3	3.66 m	84.9 d	3'	3.54 m	78.9 d
4a	2.57 m	37.3 t	4'	3.49 m	82.4 d
4b	2.49 m		5'	3.57 m	71.8 d
5		139.7 s	6'	1.42 d (6.5)	18.4 q
6	5.47 m	120.8 d	3'-OCH ₃	3.54 s	57.8 q
7a	2.66 m	28.4 t	1''(β -D-Cym)	5.26 dd (9.5, 2.0)	98.3 d
7b	2.18 m		2''a	2.29 ddd (13.0, 4.0, 2.0)	36.9 t
8	2.51 m	40.2 d	2''b	1.76 m	
9	1.34 m	53.0 d	3''	3.90 dd (6.0, 2.5)	77.8 d
10		39.5 s	4''	3.45 dd (9.0, 2.5)	82.2 d
11a	2.56 m	23.8 t	5''	4.19 ddd (12.5, 9.0, 6.0)	69.5 d
11b	1.38 m		6''	1.37 d (6.5)	18.5 q
12a	2.13 dd (13.0, 4.0)	30.0 t	3''-OCH ₃	3.55 s	58.3 q
12b	1.42 m		1'''(α -L-Cym)	4.98 dd (4.5, 1.0)	98.9 d
13		114.3 s	2'''a	2.38 ddd (15.0, 4.0, 2.0)	32.0 t
14		175.3 s	2'''b	1.82 m	
15a	4.25 dd (9.5, 8.5)	67.7 t	3'''	3.72 dd (7.0, 4.0)	76.3 d
15b	3.95 dd (8.5, 7.0)		4'''	3.61 m	73.3 d
16	5.46 m	75.5 d	5'''	4.55 ddd (13.0, 9.0, 6.5)	66.3 d
17	3.56 m	56.1 d	6'''	1.54 d (6.5)	18.6 q
18	6.49 s	143.8 d	3'''-OCH ₃	3.38 s	56.5 q
19	0.93 s	18.9 q			
20		118.5 s			
21	1.55 s	24.7 q			

^a The assignments were based on DEPT, ^1H - ^1H COSY, HMQC, and HMBC experiments. δ in ppm, J values in parentheses.

values with those reported in the literatures.^{11–14} The relative configuration of **2** was determined by NOESY correlations of H-19/H-2 and H-8 and H-16/H-17 and H-21. According to the above analyses, the structure of **2** was elucidated as glaucogenin A 3-O- α -L-cymaropyranosyl-(1 \rightarrow 4)- β -D-cymaropyranosyl-(1 \rightarrow 4)- β -D-oleandropyranose, and was designated cynanside B.

Compounds **3–5** were identified by comparing the ^1H and ^{13}C NMR, and MS spectra with the literature. They were determined to be paeonol (**3**),¹⁵ 3-hydroxy-4-methoxyacetophenone (**4**),¹⁶ and 3,4-*seco*-lup-20(29)-en-3-oic acid methyl ester (**5**).¹⁷

All isolates (**1–5**) were evaluated for their cytotoxicity against A549 (non small cell lung adenocarcinoma), SK-OV-3 (ovarian

cancer cells), SK-MEL-2 (skin melanoma), and HCT-15 (colon cancer cells) human tumor cell lines using SRB assays *in vitro*.¹⁸ Compounds **1** and **2** had selective cytotoxicity against SK-MEL-2 cells, with IC₅₀ values of 26.55 and 17.36 μM, respectively. However, both compounds were inactive against the other cell lines (IC₅₀ >30 μM). The other compounds were inactive against the four tested cell lines (IC₅₀ >30 μM).

1. Experimental section

1.1. General methods

Optical rotations were obtained on a JASCO P-1020 polarimeter. IR spectra were recorded on a Bruker Vector 22 IR spectrophotometer. NMR spectra including ¹H–¹H COSY, HMQC, HMBC and NOESY, were recorded on a Varian UNITY INOVA 500 NMR spectrometer operating at 500 MHz (¹H) and 125 MHz (¹³C) and Bruker AVANCE III 700 NMR spectrometer operating at 700 MHz (¹H). HR-FAB-MS were conducted using a JEOL JMS700 mass spectrometer. Preparative HPLC was performed using a Gilson 306 pump with a Shodex refractive index detector. Silica gel 60 (230–400 mesh, Merck) and RP-C₁₈ silica gel (230–400 mesh, Merck) were used for column chromatography. TLC was performed using Merck precoated Silica gel F₂₅₄ plates and RP-18 F_{254s} plates. Spots were detected on TLC under UV light or by heating after spraying with 10% v/v H₂SO₄ in ethanol (EtOH).

1.2. Plant materials

The roots of *C. paniculatum* were collected in Taebaek City, Korea during June 2011. The plant was identified by one of the authors (K. R. Lee). A voucher specimen (SKKU-NPL 1103) of the plant was deposited at the herbarium of the School of Pharmacy at the Sungkyunkwan University, Suwon, Korea.

1.3. Extraction and isolation

The dried roots of *C. paniculatum* (3.6 kg) were pulverized and extracted with 80% MeOH at room temperature. The MeOH extract was concentrated under reduced pressure to afford a viscous concentrate (750 g), which was suspended in water (800 mL) and solvent-partitioned to yield *n*-hexane (75 g), CHCl₃ (50 g), EtOAc (9 g), and BuOH (60 g) layers. The CHCl₃ layer (20 g) was separated over a silica gel column (230–400 mesh, 500 g) with *n*-hexane:EtOAc:MeOH (3:1:0.5) to give seven fractions (fr. C1–C7). Fr. C3 (4 g) was separated on a RP-C₁₈ silica gel column (230–400 mesh, 150 g) with a gradient solvent system of MeOH/H₂O (3:2, 4:1, 9:1, and 1:0) to give seven subfractions (fr. C31–C37). Fr. C33 (700 mg) was further separated over a silica gel column with CHCl₃:MeOH (60:1) to give three subfractions (fr. C331–C336). Fr. C332 (100 mg) was purified with a silica gel prep. HPLC with CHCl₃:MeOH (60:1) at a flow rate of 2.0 mL/min to give **1** (4 mg, *t*_R = 19.1 min). Fr. C34 was separated over a silica gel column with CHCl₃:MeOH (65:1) and further purified by a silica gel prep. HPLC with CHCl₃:MeOH (80:1) to yield **2** (7 mg, *t*_R = 15.4 min). The *n*-hexane layer (20 g) was separated over a silica gel column (230–400 mesh, 500 g) with *n*-hexane:EtOAc (15:1) to give eight fractions (fr. H1–H8). Fr. H1 (890 mg) was further separated over a Sephadex LH-20 column with CH₂Cl₂:MeOH (1:1) and purified by a silica gel prep. HPLC with *n*-hexane:EtOAc (12:1) to yield **5** (22 mg, *t*_R = 13.4 min). Fr. H2 was separated over a RP-C₁₈ silica gel column with 75% MeOH, Sephadex LH-20 column with CH₂Cl₂:MeOH (1:1), and RP-C₁₈ silica gel prep. HPLC with 50% CH₃CN to yield **3** (19 mg, *t*_R = 16.3 min). Fr. H8 was further separated over a RP-C₁₈ silica gel column with 75% MeOH and purified by a

gel preparative HPLC with *n*-hexane:EtOAc (2:1) to yield **4** (7 mg, *t*_R = 17.2 min).

1.3.1. Cynanside A (1)

Amorphous gum, [α]_D²⁵ –6.0 (c 0.05, MeOH); IR (KBr) ν_{max}: 3416, 3080, 3029, 1647, 1582, 1213, 1148, 1069, 1028 cm⁻¹; ¹H NMR (C₅D₅N, 500 MHz) and ¹³C NMR (C₅D₅N, 125 MHz) see Table 1; HR-FAB-MS *m/z* 831.4144 [M+Na]⁺ (calcd for C₄₂H₆₄NaO₁₅, 831.4143).

1.3.2. Cynanside B (2)

Amorphous gum, [α]_D²⁵ –34.0 (c 0.05, MeOH); IR (KBr) ν_{max}: 3420, 3082, 3030, 1650, 1580, 1215, 1146, 1069, 1028 cm⁻¹; ¹H NMR (C₅D₅N, 500 MHz) and ¹³C NMR (C₅D₅N, 125 MHz) see Table 2; HR-FAB-MS *m/z* 831.4144 [M+Na]⁺ (calcd for C₄₂H₆₄NaO₁₅, 831.4143).

1.4. Acid hydrolysis of 1 and 2

Compound **1** (1.0 mg) was heated at 60 °C and stirred with 1 mL of 0.02 N H₂SO₄ for 1 h. After cooling, the hydrolysate was extracted with CHCl₃ and the extract was evaporated *in vacuo* to yield a compound **1a** as an amorphous gum. Compound **2** was treated similar as **1** to yield **2a**.

1.4.1. Cynangenin A (1a)

Amorphous gum, [α]_D²⁵ –17.5 (c 0.05, MeOH); ¹H NMR (CDCl₃, 700 MHz): δ_H 5.72 (1H, m, H-16), 5.50 (1H, s, H-18), 5.49 (1H, m, H-12), 5.32 (1H, m, H-6), 4.29 (1H, dd, *J* = 10.3, 7.4 Hz, H-15a), 3.88 (1H, dd, *J* = 10.3, 5.3 Hz, H-15b), 3.59 (1H, m, H-3), 3.45 (3H, s, H-18-OCH₃), 1.59 (3H, s, H-21), 0.99 (3H, s, H-19); HR-FAB-MS *m/z* 391.2123 [M+H]⁺ (calcd for C₂₂H₃₁O₆, 391.2121).

1.4.2. Glaucogenin A (2a)

Amorphous gum, [α]_D²⁵ +74.5 (c 0.35, MeOH); ¹H NMR (C₅D₅N, 500 MHz): 6.48 (1H, s, H-18), 5.44 (1H, m, H-16), 5.41 (1H, m, H-6), 4.25 (1H, dd, *J* = 10.0, 8.5 Hz, H-15a), 3.96 (1H, dd, *J* = 8.5, 7.0 Hz, H-15b), 3.56 (1H, m, H-17), 1.54 (3H, s, H-21), 0.99 (3H, s, H-19); FAB-MS *m/z* 399.2 [M+Na]⁺.

1.5. Determination of the absolute configurations of sugars

The sugar obtained from the hydrolysis of **1** was dissolved in anhydrous pyridine (0.5 mL) followed by adding of *L*-cysteine methyl ester hydrochloride (2.0 mg), and the mixture was stirred at 60 °C for 1.5 h. Acetic anhydride (0.5 mL) was added and heated for another 1 h. The mixture was partitioned between *n*-hexane and H₂O (1.0 mL each), and the organic layer (1.0 μL) was analyzed by GC/MS. Identification of *D*-oleandrose and *D*-digitoxose was performed by co-injection of the hydrolysate with standard acetylated samples (*D*-oleandrose, hydrolyzed from cynapanoside A;¹⁰ *D*-digitoxose, Sigma–Aldrich), giving a single peak at 6.238 min (*D*-oleandrose) and 9.476 min (*D*-digitoxose). Compound **2** (1.0 mg) was treated as above and yielded aglycone **2a** and sugars. *D*-Oleandrose was identified by GC/MS (*R*_f = 6.268 min). GC conditions in the test: column, HP-5MS UI, 30 m × 0.25 mm, 0.25 μm; detection, MS; carrier gas, He; injection temperature, 250 °C, detection temperature, 280 °C, column temperature, 150 °C (0 min), 10 °C/min to 250 °C (20 min). *R*_f *D*-oleandrose 6.246 min.

D-Oleandrose, *L*-oleandrose, *D*-cymarose, *L*-cymarose, and *D*-digitoxose were identified by co-TLC with standard samples and comparison of *R*_f values with the literature;¹³ *D*,*L*-oleandrose (CHCl₃:MeOH = 8:1, *R*_f value: 0.48), *D*, *L*-cymarose (CHCl₃:MeOH = 8:1, *R*_f value: 0.52), and *D*-digitoxose (CHCl₃:MeOH = 8:1, *R*_f value: 0.40).

1.6. Cytotoxicity assay

A SRB bioassay was used to determine the cytotoxicity of each compound isolated against four cultured human tumor cell lines.¹⁸ The assays were performed at the Korean Research Institute of Chemical Technology. The cell lines used were A549, SK-OV-3, SK-MEL-2, and HCT-15. Doxorubicin was used as a positive control. The cytotoxicities of doxorubicin against the A549, SKOV-3, SK-MEL-2, and HCT-15 cell lines were IC₅₀ 0.029, 0.036, 0.001, and 2.041 μM, respectively.

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (20110028285). We thank the Korea Basic Science Institute (KBSI) for the NMR and MS spectral measurements.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.carres.2013.08.023>.

References

1. Meng, Z. Y.; Zhang, J. Y.; Xu, S. X.; Sugahara, K. *Planta Med.* **1999**, *65*, 661–663.
2. Zhou, L.-B.; Chen, T.-H.; Bastow, K. F.; Shibano, M.; Lee, K.-H.; Chen, D.-F. *J. Nat. Prod.* **2007**, *70*, 1263–1267.
3. Kim, K. H.; Kim, M. A.; Moon, E.; Kim, S. Y.; Choi, S. Z.; Son, M. W.; Lee, K. R. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2075–2078.
4. Kim, C. S.; Kim, S. Y.; Moon, E.; Lee, M. K.; Lee, K. R. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 1771–1775.
5. Achenbach, H.; Huebner, H.; Brandt, W.; Reiter, M. *Phytochemistry* **1994**, *35*, 1527–1543.
6. Chen, G.; Xu, N.; Li, Z.-F.; Zhang, Q.-H.; Wu, H.-H.; Pei, Y.-H. *J. Asian Nat. Prod. Res.* **2010**, *12*, 453–457.
7. Peng, Y.-R.; Li, Y.-B.; Liu, X.-D.; Zhang, J.-F.; Duan, J.-A. *Phytomedicine* **2008**, *15*, 1016–1020.
8. Day, S.-H.; Wang, J.-P.; Won, S.-J.; Lin, C.-N. *J. Nat. Prod.* **2001**, *64*, 608–611.
9. Brasholz, M.; Reißig, H.-U. *Eur. J. Org. Chem.* **2009**, 3595–3604.
10. Oh, J. Y.; Kim, C. S.; Lee, K. R. *Bull. Korean Chem. Soc.* **2013**, *34*, 637–640.
11. Chen, H.; Xu, N.; Zhou, Y.; Qiao, L.; Cao, J.; Yao, Y.; Hua, H.; Pei, Y. *Steroids* **2008**, *73*, 629–636.
12. Yu, J.-Q.; Deng, A.-J.; Qin, H.-L. *Steroids* **2013**, *78*, 79–90.
13. Ma, L.-F.; Shan, W.-G.; Zhan, Z.-J. *Helv. Chim. Acta* **2011**, *94*, 2272–2282.
14. Bai, H.; Li, W.; Koike, K.; Satou, T.; Chen, Y.; Nikaido, T. *Tetrahedron* **2005**, *61*, 5797–5811.
15. Yasuda, T.; Kon, R.; Nakazawa, T.; Ohsawa, K. *J. Nat. Prod.* **1999**, *62*, 1142–1144.
16. Rosiak, A.; Frey, W.; Christoffers, J. *Eur. J. Org. Chem.* **2006**, 4044–4054.
17. Castro, V. A.; Garcia, C.; Gonzalez, A. G.; Hernandez, R.; Suarez, E. *Phytochemistry* **1980**, *19*, 2210–2212.
18. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. *J. Natl. Cancer Inst.* **1990**, *82*, 1107–1112.